Administrative Core

行政核心

• 批准号: 7474413
• 负责人: Joel S. Bennett
• 金额: $ 7.02万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7474413
• 关键词: Administrator; Advisory Committees; Antibodies; Antibody Formation; Apple; Area; Biology; Blood Platelets; Budgets; Businesses; CXCR4 gene; Cardiovascular system; Charge; Complex; Computers; Cytoplasmic Tail; Electronic Mail; Endothelial Cells; Epitopes; Equipment and Supplies; Expenditure; F2R gene; Floor; Flow Cytometry; Funding; Future; Glycoproteins; Hematology; Human; Hybridomas; Individual; Manuscripts; Monitor; Monoclonal Antibodies; Mus; Numbers; PAC1 phosphatase; Participant; Pediatric Hospitals; Pennsylvania; Peptides; Photocopying; Platelet Glycoproteins; Price; Principal Investigator; Production; Recommendation; Research; Research Personnel; Services; Site; Specialist; System; Telephone; Thinking; Thrombin Receptor; Thrombosis; Universities; Visit; Wages; base; chemokine receptor; computerized; cost; day; discount; experience; interest; member; oncology; programs

The Administrative Core is essential for the conduct of this Program Project. It will continue to be based in the administrative area of the Hematology-Oncology Division at the University of Pennsylvania. The Core provides administrative support for the participants in the Program Project, as well as secretarial, and consultative functions and the supplies needed to support these functions. In addition, A. Administrative Functions To provide financial coordination for the Program Project, the Core Unit B leader and an experienced business administrator, Ms. Michele Arlotta, monitor the expenditures of each Project and Core Unit, facilitated by a system of computerized record keeping. Project leaders and Core Unit Leaders will be provided with monthly statements of the financial status of their projects or core units. Core Unit B will also serve to centralize the ordering of supplies and equipment, enabling the business administrator to monitor these expenditures and to take advantage of discounted prices available through the University. The business administrator will also oversee matters relating to the consortia with the Division of Hematology at the Children's Hospital of Pennsylvania and Thomas Jefferson University. B. Secretarial functions The Program Project will make use of 35% of the effort of a secretary, Mrs Terese Manganaro, who is based on the 9th floor of BRB 11/111 of the University of Pennsylvania. Mrs. Manganaro will type manuscripts and correspondence generated by the activities of the Program. She has an Apple Macintosh computer and is electronically networked to each investigator via the University of Pennsylvania E-mail network. C. Common Services and Supplies Core Unit B will provide the photocopying, postage, and telephone service needed to support the activities of the Program Project. D. Consultative functions Core Unit B will provide two types of consultative function. First, at monthly intervals, an outside investigator whose interests coincide with those of the members of the Program Project will be asked to a spend a day at the University, meet with the various Project leaders and Co-Investigators, and present a seminar at the weekly Thrombosis & Cardiovascular Biology Seminar. Funds required for these visitors in excess of those requested in the Core Unit Budget will be provided by other funds available to the Hematology-Oncology Division. Second, an External Advisory Committee composed of three members will be selected if and when the Program Project is re-funded. The Committee will be asked to visit the Program Project on a yearly basis, review its progress, and make specific recommendations regarding future directions. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page Continuation Format Page ,329 Principal Investigator/Program Director (Last, First, Middle): Bennett, Joel S. E. Continued Supply of Monoclonal Antibodies Since the inception of this Program Project, a Hybridoma Core (Core A), has produced a number of monoclonal antibodies (mAbs) to platelet and endothelial glycoproteins that have been highly useful to the Program. These include: A. Monoclonal antibodies to platelets glycoproteins allbfJS. Multiple antibodies have been produced by the Core to platelet allbbS and continue to be extensively utilized. These include mAbs specific for allb; (33; the allb(33 complex; activation-specific epitopes on the allb(33 complex; antiidiotypic mAbs to the activation-specific, anti allbps mAb PAC-1; and the cytoplasmic domains of allb and (33. B. Monoclonal antibodies to the human thrombin receptor (PAR1). The Core has had a particularly productive track-record in producing mAbs to epitopes on amino terminus of human PAR1 that have been useful in studies of platelets and endothelial cells. C. Monoclonal antibodies to the human PAR2. Antibodies to the PAR2 amino terminus (SAM11 and SAM12) have also been generated from mice immunized with the peptide, SLIGKVDGTSHVTG, corresponding to the first 14 residues of human PAR-2 starting at the activation site (Arg36-Ser37). The mAbs have been particularly useful for flow cytometry and immunohistochemical studies. D. Miscellaneous antibodies. Additional antibodies produced by the Core that have been used by Core members include mAbs to CD9 and the chemokine receptor CXCR4. At the renewal for Years 16-20, Core A was not recommended. However, because projects in the Program continued to use the mAbs listed above, funds were restored to enable continuing production of the antibodies. In this application, we have not proposed the production of new mAbs within the Program and have not requested continuation of Core A. But all of the project continue to make extensive use of one or more of these mAbs and therefore, we have requested modest partial salary support for a Research Specialist to produce them. Costs for supplies will be charged to individual projects as necessary. Although the Research Specialist does not perform an "administrative" function, she does perform a Program-wide function and we think Core B would be the most appropriate place to request support for her salary.

管理核心对本计划项目的实施至关重要。它将继续是 总部设在加州大学血液病和肿瘤科的行政区域 宾夕法尼亚州。核心为计划项目的参与者提供行政支持， 以及秘书和咨询职能以及支助这些职能所需的用品。 此外, A.行政职能 为计划项目提供财务协调，核心单位B领导和经验丰富的 业务主管米歇尔·阿洛塔女士监督每个项目和核心单位的支出， 由计算机化的记录保存系统促进。项目负责人和核心单位负责人将 每月向其项目或核心单位提供财务状况报表。核心单元B 还将用于集中订购用品和设备，从而使业务 管理员监控这些支出并利用可用的折扣价格 通过这所大学。业务管理人还将监督与财团有关的事务 宾夕法尼亚儿童医院血液科和托马斯·杰斐逊 大学。 B.秘书职能 该计划项目将利用秘书Terese Manganaro夫人35%的努力，她是 基于宾夕法尼亚大学BRB 11/111号楼9楼。Manganaro夫人会打字 本计划活动产生的手稿和函件。她有一个苹果 Macintosh计算机，并通过加州大学与每位研究人员建立电子网络 宾夕法尼亚州电子邮件网络。 C.共同事务和用品 核心单位B将提供影印、邮资和电话服务，以支持 计划项目的活动。 D.协商职能 核心单位B将提供两种类型的咨询职能。首先，每隔一个月，一个外部 与计划项目成员的兴趣一致的调查员将被要求 在大学呆上一天，会见不同的项目负责人和协查人员，以及 在每周一次的血栓形成和心血管生物学研讨会上发表一次研讨会。所需资金用于 这些来访者超过核心单位预算要求的人数，将由其他基金提供 提供给血液科-肿瘤科。第二，由一个外部咨询委员会组成 如果计划项目重新获得资金，将选择三名成员中的一名。委员会将 被要求每年访问计划项目，审查其进展情况，并做出具体 关于未来方向的建议。 PHS 398/2590(09/04版，2006年4月4日重新发布)页面续格式页面 ，329 首席调查员/项目主任(最后、第一、中间)：Bennett，Joel S. E.持续供应单抗 自该方案项目开始以来，一个杂交瘤核心(核心A)已经产生了许多 抗血小板和内皮糖蛋白的单抗(MAbs)非常有用 加入该计划。这些措施包括： 抗血小板膜糖蛋白AlbfJS的单抗。已经发现了多种抗体 由核心生产到血小板的allbbS，并继续广泛使用。其中包括单抗 Allb的特异性；(33；Allb(33个复合体；Allb上的激活特异性表位(33个复合体；抗独特型 抗Al1b激活特异性mAbPAC-1的单抗和Al1b的细胞质结构域 和(33. B.抗人凝血酶受体(PAR1)的单抗。核心已经有了一个 在生产针对人PAR1氨基末端表位的单抗方面的卓有成效的记录 在血小板和内皮细胞的研究中很有用。 C.抗人PAR2的单抗。抗PAR2氨基末端抗体(SAM11 和SAM12)也已从SLIGKVDGTSHVTG免疫的小鼠中产生， 对应于人PAR-2在激活位点(Arg36-Ser37)开始的前14个残基。 单抗在流式细胞术和免疫组织化学研究中特别有用。 D.各种抗体。由Core产生的其他抗体，已由 核心成员包括抗CD9的单抗和趋化因子受体CXCR4。 在16-20年的续签中，不推荐使用核心A。然而，由于 计划继续使用上面列出的单抗，资金已恢复以支持继续 抗体的产生。在本申请中，我们没有提出生产新的单抗 在该计划内，并未要求继续执行核心A，但所有项目仍在继续 广泛使用这些单抗中的一个或多个，因此，我们要求适度的部分 为一名研究专家提供工资支持，以制作它们。供应费将计入 个别项目视需要而定。尽管研究专家不会执行 “行政”职能，她确实履行了整个计划的职能，我们认为核心B将是 请求支持她的工资的最合适的地方。